Risk stratified follow-up for endometrial cancer: the clinicians’ perspective
Risk-stratified follow-up for endometrial cancer (EC) is being introduced in many cancer centres, however there appears to be diversity in the structure and availability of schemes across the UK. This study aimed to investigate clinicians’ and clinical specialist nurses’ (CNS) experiences of follow-up schemes for EC, including patient-initiated follow-up (PIFU), telephone follow-up (TFU) and clinician-led hospital follow-up (HFU). A mixed-methods study was conducted consisting of an online questionnaire to CNSs, an audience survey of participants attending a national ‘Personalising endometrial cancer follow-up’ educational meeting, and qualitative semi-structured telephone interviews with clinicians involved in the follow-up of EC. Thematic analysis identified three main themes to describe clinicians’ views: appropriate patient selection; changing from HFU to PIFU schemes; and the future of EC follow-up schemes. Many participants reported that the Covid-19 pandemic impacted on EC follow-up by accelerating the transition to PIFU/TFU. Overall, there was increasing support for non-HFU schemes for patients who have completed primary treatment of EC, however barriers were identified for non-English speaking patients and those who had communication challenges. Given the good long-term outcome associated with EC, greater focus is needed to develop resources to support patients post-treatment and individualise follow-up according to patients’ personal needs and preferences.
Funding
Leicester Institute for Advanced Studies
Wellcome Trust Institutional Strategic Support Fund
History
School
- Sport, Exercise and Health Sciences
Published in
Current OncologyVolume
30Issue
2Pages
2237-2248Publisher
MDPIVersion
- VoR (Version of Record)
Rights holder
© The authorsPublisher statement
This article is an Open Access article published by MDPI and distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).Acceptance date
2023-02-02Publication date
2023-02-13Copyright date
2023eISSN
1718-7729Publisher version
Language
- en